List of Excipients in Branded Drug DEFINITY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lantheus Medical Imaging Inc	DEFINITY	perflutren	11994-011	GLYCERIN	2037-05-04
Lantheus Medical Imaging Inc	DEFINITY	perflutren	11994-011	PROPYLENE GLYCOL	2037-05-04
Lantheus Medical Imaging Inc	DEFINITY	perflutren	11994-011	SODIUM CHLORIDE	2037-05-04
Lantheus Medical Imaging Inc	DEFINITY	perflutren	11994-011	SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE	2037-05-04
Lantheus Medical Imaging Inc	DEFINITY	perflutren	11994-011	SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE	2037-05-04
Lantheus Medical Imaging Inc	DEFINITY RT	perflutren	11994-017	ACETIC ACID	2037-05-04

# DEFINITY Excipient Strategy and Commercial Opportunities: Formulation, Manufacturing, Patent Risk, and Generic Entry

Last updated: August 10, 2026

DEFINITY is a perflutren lipid microsphere ultrasound contrast agent marketed by Lantheus Medical Imaging. Its commercial value depends less on the perflutren gas alone than on the excipient system, microsphere-size distribution, activation process, stability profile, and hospital workflow. The core formulation uses a phospholipid shell with a polyethylene glycol-lipid component surrounding perflutren gas. These materials create the acoustic response, control circulation time, and determine manufacturing complexity.[1]

The strongest commercial opportunities are in lipid excipient supply, microsphere manufacturing, activation-device integration, regional supply, and differentiated ultrasound contrast products. The principal entry barriers are process control, sterile manufacturing, gas retention, container-closure performance, analytical characterization, and clinical equivalence.

What is the DEFINITY formulation and which excipients control performance?

DEFINITY is a sterile injectable suspension of perflutren lipid microspheres for use in contrast-enhanced echocardiography and other ultrasound imaging applications. The microspheres contain perflutren gas within a lipid shell and are supplied in a vial that requires mechanical activation before administration.[1]

DEFINITY formulation components

Component	Formulation role	Commercial relevance
Perflutren gas	Echogenic core that produces ultrasound backscatter	Requires controlled gas handling, filling, and retention
DPPC, or 1,2-dipalmitoyl-sn-glycero-3-phosphocholine	Primary structural phospholipid in the microsphere shell	Critical to shell formation and acoustic performance
PEG-lipid, identified in the label as MPEG5000-DPPE	Steric stabilization and control of microsphere behavior	Creates specialized lipid sourcing and characterization requirements
Aqueous vehicle	Maintains the injectable suspension	Requires control of pH, osmolality, sterility, and particulate burden
Vial and activation system	Preserves the product before use and generates the final microsphere suspension	Creates device, packaging, and workflow dependencies

FDA labeling describes DEFINITY as containing microspheres with a mean diameter in the low-micron range and a defined concentration of microspheres per milliliter.[1] The narrow size profile is commercially important. Larger or poorly distributed particles can alter circulation, acoustic intensity, filtration behavior, and safety performance.

The excipient system is therefore functional rather than passive. DPPC contributes the primary shell structure. The PEG-lipid improves colloidal stability and modifies the interface between the lipid shell and the blood environment. The combination must produce a reproducible population of microspheres after activation, not merely a chemically equivalent mixture.

How does the DEFINITY excipient strategy create product differentiation?

DEFINITY uses an engineered lipid-gas interface. Its product differentiation comes from the interaction of four variables:

1. Shell composition.
2. Perflutren loading.
3. Microsphere size and concentration.
4. Activation and delivery conditions.

The same nominal excipients can produce materially different products if the manufacturing process changes. Homogenization energy, gas-to-liquid ratio, temperature, lipid concentration, mixing time, vial headspace, and activation force can affect particle size and acoustic behavior.

Why DPPC is strategically important

DPPC is a naturally occurring phospholipid and a common building block for lipid-based drug delivery systems. In DEFINITY, it provides the principal mechanical structure around the perflutren core. Its melting behavior, purity, oxidation profile, and acyl-chain composition affect shell uniformity.

A pharmaceutical-grade DPPC supplier can create value through:

• Tight control of oxidation and hydrolysis products.
• Consistent particle-free handling.
• Low bioburden and endotoxin specifications.
• Lot-to-lot control of fatty-acid composition.
• Documentation suitable for an injectable product.
• Supply continuity for a relatively specialized excipient.

Commodity phospholipid pricing alone is unlikely to determine the economics of a competing product. The more important issue is validated quality and reproducible performance in the complete microsphere process.

Why the PEG-lipid matters

MPEG5000-DPPE is a specialized functional excipient. The PEG chain provides steric stabilization, while the DPPE anchor associates with the lipid shell. The material requires tighter characterization than a conventional small-molecule excipient because the PEG molecular-weight distribution, substitution level, residual solvents, lipid purity, and degradation products can influence the final microspheres.

Potential control attributes include:

• PEG molecular-weight distribution.
• Degree of lipid substitution.
• Residual free PEG.
• Residual solvents.
• Phospholipid oxidation.
• Hydrolytic degradation.
• Trace metals.
• Microbial and endotoxin burden.

A manufacturer that can supply a qualified MPEG-lipid with a robust regulatory package has a higher-value opportunity than a supplier offering an unqualified raw material.

What manufacturing barriers protect DEFINITY from rapid generic competition?

The primary barriers are process and analytical rather than the basic identity of the excipients.

Microsphere formation

A competitor must reproduce the critical quality attributes of the reference product, including:

• Microsphere concentration.
• Mean diameter and particle-size distribution.
• Perflutren content.
• Gas retention.
• Lipid concentration.
• Surface composition.
• Acoustic response.
• In-use stability after activation.
• Syringeability and injectability.
• Sterility and endotoxin control.

For an injectable suspension, comparative chemistry alone is insufficient. The sponsor must demonstrate that the product behaves consistently during preparation and administration. Small differences in particle size can affect both imaging performance and safety-related characteristics.

Activation process

DEFINITY uses a dedicated activation step. The vial is mechanically activated before administration, and the activation procedure is part of the product's practical identity. A rival product could pursue one of several approaches:

• A vial activated by a proprietary mechanical device.
• A ready-to-use suspension.
• A manually agitated presentation.
• A prefilled syringe.
• An automated injector-compatible product.

Each approach changes the regulatory and commercial profile. A ready-to-use product could reduce operator burden but would face more demanding stability and container-closure requirements. A device-based product could preserve a dry or partially stabilized intermediate but would create combination-product and manufacturing dependencies.

Analytical comparability

The most difficult analytical problem is linking physicochemical data to clinical imaging performance. Conventional tests such as assay, pH, osmolality, and sterility do not fully characterize an ultrasound microsphere product.

A competitive analytical package would likely include:

• Laser diffraction or equivalent particle sizing.
• Microscopy for morphology.
• Gas-content testing.
• Acoustic attenuation and backscatter measurements.
• Microsphere count and concentration.
• Shell-lipid composition.
• In-use stability after activation.
• Container-closure integrity.
• Stress testing under transport and storage conditions.

FDA guidance for injectable products and drug-device combinations supports a risk-based approach to critical quality attributes and manufacturing controls.[2,3]

What is the FDA regulatory status of DEFINITY?

DEFINITY was approved by FDA under NDA 021064 as an injectable ultrasound contrast agent. It is used primarily for contrast-enhanced echocardiography, including assessment of left ventricular opacification and endocardial border delineation.[1]

Regulatory item	DEFINITY status
Active ingredient	Perflutren
Product type	Lipid microsphere injectable suspension
Sponsor/marketer	Lantheus Medical Imaging
FDA pathway	NDA approval
Main clinical category	Ultrasound diagnostic contrast
Administration	Intravenous
Preparation	Vial activation before use
Biosimilar pathway	Not applicable
Generic pathway	Potentially ANDA or 505(b)(2), depending on sameness and product differences

DEFINITY is a drug product, not a biologic. A biosimilar application under the Public Health Service Act is therefore not the relevant competitive pathway. A follow-on sponsor would instead assess an abbreviated application or a 505(b)(2) application under the Federal Food, Drug, and Cosmetic Act.

The regulatory route will depend on whether the proposed product matches the reference product in formulation, dosage form, route, strength, labeling, device configuration, and performance. A materially different activation system, formulation, or clinical use could move the product toward 505(b)(2) development.

What is the Orange Book status of DEFINITY?

DEFINITY's relevant regulatory record is associated with NDA 021064. The Orange Book should be reviewed for the current listing status, patent entries, and exclusivity information before a filing or litigation decision.[4]

A practical assessment is:

• DEFINITY's original approval is more than two decades old.
• New-drug exclusivity associated with the original approval has expired.
• The principal commercial barrier is unlikely to be unexpired regulatory exclusivity.
• Any current patent risk would depend on listed patents, later-approved supplements, device rights, manufacturing patents, or non-Orange-Book intellectual property.
• Diagnostic contrast products can have meaningful process and device barriers even when the Orange Book does not create a long remaining exclusivity period.

When does DEFINITY lose exclusivity?

DEFINITY's original FDA exclusivity has expired. The relevant question for a new entrant is not loss of original exclusivity but whether any currently enforceable patents, formulation claims, device claims, or regulatory exclusivity attach to the specific product presentation being challenged.

A sponsor evaluating entry should separate:

1. FDA exclusivity.
2. Orange Book-listed patents.
3. Unlisted formulation and process patents.
4. Device and activation-system rights.
5. Trade secrets and manufacturing know-how.
6. Contractual supply restrictions.

What patents protect DEFINITY and its excipient system?

The DEFINITY technology platform has historically been associated with patents covering gas-filled microspheres, lipid shells, ultrasound contrast compositions, and manufacturing processes. Patent protection for the earliest platform inventions is generally old relative to the 2001 FDA approval and may have expired or entered the public domain, depending on the specific patent family and terminal-disclaimer history.

A patent review should distinguish between:

IP category	Potential claim scope	Entry risk
Composition patents	Gas-filled lipid microspheres and shell materials	Lower for early expired families; higher for later improvements
Excipient-ratio patents	Specific DPPC, PEG-lipid, or auxiliary-lipid proportions	Moderate if claims remain enforceable
Size-distribution patents	Defined microsphere populations or acoustic properties	Moderate to high if tied to clinical performance
Process patents	Formation, loading, activation, or stabilization methods	Often difficult to detect from the formulation alone
Device patents	Vial activation, mixing, or delivery systems	Relevant to proprietary activation workflows
Use patents	Echocardiographic or imaging indications	Usually narrower than composition claims
Trade secrets	Process parameters and scale-up conditions	High practical value even without patent protection

The excipient strategy may be protected indirectly. A claim directed to a microsphere composition can encompass the lipid shell and gas core without naming every manufacturing parameter. A process claim can protect the way the shell is formed even if competing companies can purchase the same DPPC and PEG-lipid.

What patent challenges could a DEFINITY generic face?

A prospective ANDA applicant would evaluate Paragraph IV certifications against any listed patents. A 30-month stay could arise if the NDA holder files an infringement action within the statutory period after receiving a Paragraph IV notice.[5]

The main Paragraph IV questions would be:

• Whether the proposed product has the same active ingredient and dosage form.
• Whether its microsphere size and concentration fall within a listed claim.
• Whether the activation device is part of a patented combination.
• Whether manufacturing steps are practiced by the applicant or a contract manufacturer.
• Whether the applicant can design around shell-composition or process claims.
• Whether a commercial launch would require a litigation-risk assessment.

Because composition and process claims may not align cleanly with FDA sameness standards, a 505(b)(2) strategy could be attractive for a differentiated product but would require a more substantial clinical and regulatory package.

Which companies are positioned to challenge DEFINITY?

The competitive field includes established ultrasound contrast suppliers, diagnostic-imaging companies, contract development and manufacturing organizations, and specialized lipid-excipient manufacturers.

Direct and adjacent competitors

Company type	Commercial opportunity
Established ultrasound contrast companies	Launch a directly substitutable lipid microsphere product
Generic injectable manufacturers	Develop an ANDA or 505(b)(2) follow-on
Diagnostic imaging companies	Pair contrast agents with ultrasound systems and workflow software
Lipid nanoparticle manufacturers	Transfer microsphere formulation and sterile-processing expertise
CDMOs	Offer development, scale-up, aseptic filling, and analytical testing
Excipient suppliers	Sell qualified DPPC and PEG-lipid materials
Device manufacturers	Develop activation, injection, and automated-dosing systems

The strongest challengers are likely to be companies with existing sterile injectable infrastructure and experience in complex suspensions. A conventional generic manufacturer without microsphere analytics or gas-handling capability would face a longer development path.

What commercial opportunities exist in DEFINITY excipients?

The largest opportunity is not necessarily a direct substitute for DEFINITY. Several adjacent markets can monetize the same excipient and process capabilities.

1. Qualified lipid excipient supply

Suppliers can offer pharmaceutical-grade DPPC, DPPE-derived PEG-lipids, and related phospholipids with regulatory documentation. The opportunity is strongest where the supplier can provide:

• Multiple qualified manufacturing sites.
• Animal-origin-free documentation.
• Low-oxidation specifications.
• Change-control support.
• DMF or equivalent regulatory support.
• Long-term supply agreements.
• Small-volume development quantities and commercial-scale production.

2. Ultrasound contrast follow-ons

A follow-on product could compete on:

• Lower acquisition cost.
• Ready-to-use presentation.
• Longer post-activation stability.
• Smaller vial waste.
• Simplified activation.
• Compatibility with automated injectors.
• Improved imaging consistency.
• Expanded use in point-of-care ultrasound.

Hospitals may value workflow improvements even when image quality is similar. Products that reduce preparation steps, nursing time, or discarded doses can create a measurable economic proposition.

3. New ultrasound imaging indications

The lipid microsphere platform can support research in:

• Myocardial perfusion imaging.
• Vascular imaging.
• Liver lesion characterization.
• Renal perfusion.
• Molecular imaging.
• Targeted ultrasound delivery.
• Blood-brain barrier research.
• Drug and gene delivery.

These applications would require new clinical evidence and may require claims directed to a particular target, imaging method, or therapeutic payload. They should not be assumed to fall within DEFINITY's existing label.

4. Combination products and devices

An activation device can create defensible commercial differentiation. Opportunities include:

• Automated vial activation.
• Dose preparation systems.
• Closed-system transfer devices.
• Injector integration.
• Barcode-based dose tracking.
• Ultrasound-machine software that standardizes contrast imaging.

The device route may create additional regulatory work, but it can also reduce direct price competition by embedding the product in a clinical workflow.

5. Regional manufacturing and supply resilience

DEFINITY-like products require specialized phospholipids, perflutren handling, aseptic processing, and validated packaging. Regional manufacturing can reduce dependence on a single supply chain and support local procurement requirements.

Potential regional strategies include:

• North American lipid and sterile-fill capacity.
• European contract manufacturing.
• Asian supply of qualified phospholipids.
• Local final assembly and packaging.
• Dual sourcing for DPPC and PEG-lipid materials.

The commercial value of regional supply is highest where hospitals and public-sector buyers place weight on continuity and domestic production.

How strong is the DEFINITY patent estate?

The patent estate should be viewed as mixed rather than uniform.

Estate component	Relative strength
Early basic gas-microsphere concepts	Weakened by age and likely expiration of foundational patents
Specific lipid-shell compositions	Potentially meaningful if later-filed claims remain active
Manufacturing process know-how	Strong practical barrier even where patent protection is limited
Activation device rights	Potentially strong for a specific device architecture
Clinical method-of-use patents	Narrower and dependent on claim construction
Trade secrets	Important for scale-up, consistency, and yield

The strongest defensibility likely comes from the combination of process know-how, analytical methods, validated supply, and clinical familiarity. A competitor may be able to reproduce the listed ingredients but still struggle to match product performance at commercial scale.

What generic launch scenarios exist for DEFINITY?

Scenario 1: Direct ANDA launch

A company develops a product with the same active ingredient, dosage form, route, strength, and labeling. The commercial advantage is a potentially shorter regulatory path. The major risks are pharmaceutical equivalence, bioequivalence or product-performance expectations, patent litigation, and manufacturing reproducibility.

Scenario 2: 505(b)(2) differentiated product

A sponsor changes the activation system, presentation, stability period, or clinical use. This may support a differentiated product but requires more evidence and can create new patent exposure.

Scenario 3: Contract-manufactured entry

A specialist CDMO develops the microspheres while a commercial partner owns the application and distribution rights. This reduces internal capital requirements but creates dependency on a narrow manufacturing base.

Scenario 4: Device-led competition

A company sells a contrast agent with a proprietary activator or injector. The product competes on hospital workflow and operational cost rather than unit price alone.

Scenario 5: Excipient-platform licensing

A lipid supplier licenses a qualified shell composition or manufacturing process to multiple developers. Revenue comes from development fees, supply agreements, and royalties rather than direct drug commercialization.

What licensing deals are commercially relevant?

Potential licensing structures for DEFINITY-related opportunities include:

• Exclusive regional rights for a follow-on contrast agent.
• Nonexclusive supply agreements for DPPC or PEG-lipid excipients.
• Co-development of an automated activation system.
• CDMO agreements covering microsphere formation and aseptic filling.
• Option-based arrangements tied to analytical comparability milestones.
• Royalty-bearing licenses for process or device patents.
• Manufacturing technology transfers with minimum purchase commitments.

The most valuable deal terms would address raw-material qualification, change control, capacity reservation, technology transfer, failure allocation, regulatory support, and rights to improvements.

What revenue exposure does DEFINITY create?

DEFINITY is commercially important because ultrasound contrast agents can increase the diagnostic utility of echocardiography without the infrastructure required for CT or MRI. Revenue exposure is concentrated in:

• Hospital echocardiography departments.
• Cardiology centers.
• Outpatient imaging facilities.
• Emergency and critical-care settings.
• Point-of-care ultrasound programs.

A generic entrant could pressure price, but the impact on the incumbent would depend on substitution, contracting, reimbursement, supply reliability, and clinical preference. A lower-priced product may not rapidly displace the reference product if hospitals prioritize consistent imaging performance and uninterrupted availability.

The most attractive commercial positioning is often a total-cost-of-use proposition. Reduced vial waste, simpler activation, longer in-use stability, and lower preparation labor can matter more than the acquisition price per vial.

Key Takeaways

• DEFINITY's excipient strategy uses a functional phospholipid shell around perflutren gas.
• DPPC provides the principal shell structure, while the MPEG5000-DPPE PEG-lipid supports stabilization and microsphere behavior.
• The main competitive barriers are microsphere formation, gas retention, size control, analytical comparability, aseptic processing, and activation technology.
• Original FDA exclusivity has expired, making current patent, device, process, and trade-secret analysis more important.
• DEFINITY is not a biosimilar product. Potential follow-on applicants would assess an ANDA or 505(b)(2) pathway.
• The strongest commercial opportunities include qualified lipid excipients, follow-on ultrasound contrast agents, automated activation systems, regional manufacturing, and platform licensing.
• Generic entry is technically feasible but requires more than reproducing the ingredient list.
• Hospital workflow, product waste, stability, and supply reliability are central competitive variables.

FAQs

Can DPPC and MPEG5000-DPPE be sold as direct DEFINITY substitutes?

No. The excipients can be used in a competing formulation, but the sponsor must reproduce the required microsphere characteristics, product performance, safety profile, and regulatory requirements.

Is perflutren the only active ingredient in DEFINITY?

Perflutren is the active gas component. The phospholipids and PEG-lipid form the functional shell and are treated as formulation components rather than independent active ingredients.[1]

Could a ready-to-use DEFINITY alternative gain a commercial advantage?

Yes. A ready-to-use product could reduce activation labor and preparation waste. Its disadvantages would include more demanding shelf-life, container-closure, gas-retention, and suspension-stability requirements.

Are lipid excipients for ultrasound contrast agents interchangeable with lipid nanoparticle excipients?

Not automatically. Both platforms use phospholipids, but ultrasound microspheres require control of gas encapsulation, particle-size distribution, shell mechanics, and acoustic response.

Does a DEFINITY competitor need to copy the Vialmix activation system?

Not necessarily. A competitor could use a different activation method, but a change in activation technology could affect regulatory pathway, product comparability, device rights, clinical workflow, and patent risk.

References

1. U.S. Food and Drug Administration. (2023). DEFINITY (perflutren lipid microsphere) injectable suspension: Prescribing information. Lantheus Medical Imaging, Inc.

2. U.S. Food and Drug Administration. (1999). Guidance for industry: Container closure systems for packaging human drugs and biologics. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2015). Q8(R2), Q9, and Q10 pharmaceutical development, quality risk management, and pharmaceutical quality system guidance. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. U.S. Department of Health and Human Services.